All In Biotech

NDA 019949 · Pfizer

Diflucan

Fluconazole · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Jan 29, 1990

Approved uses

3

Original approval plus efficacy supplements

Registered trials

259

66 Phase 3, 22 recruiting

FAERS reports

70,762

59,877 serious, 12,605 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 23, 1994 Supplement 12 · Efficacy · priority review
  • Dec 30, 1993 Supplement 3 · Efficacy
  • Jan 29, 1990 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • DIFLUCAN · FLUCONAZOLE 150MG · TABLET, ORAL · Prescription · TE AB
  • DIFLUCAN · FLUCONAZOLE 100MG · TABLET, ORAL · Prescription · TE AB
  • DIFLUCAN · FLUCONAZOLE 200MG · TABLET, ORAL · Prescription · TE AB
  • DIFLUCAN · FLUCONAZOLE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluconazole" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,269
  • off label use4,705
  • pyrexia4,261
  • nausea3,868
  • diarrhoea3,655
  • fatigue3,320
  • pain3,210
  • drug interaction3,089
  • headache2,999
  • pneumonia2,937
  • febrile neutropenia2,741
  • rash2,522

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,081
20051,191
20061,243
20071,184
20081,359
20091,567
20101,650
20112,504
20122,479
20132,100
20142,290
20153,173
20163,829
20173,887
20185,023
20195,586
20205,251
20214,995
20224,531
20234,172
20244,469
20254,315
20262,874

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diflucan (Fluconazole)

2024 spending

$335K

Beneficiaries

206

348 claims

Per beneficiary

$1,627

$23.75 per unit

View as table
YearSpending
2020$544,440
2021$539,499
2022$322,406
2023$229,457
2024$335,102

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,079 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.